Controlling minor #outbreaks is necessary to #prepare for major #pandemics

Source: PLoS Biology, Perspective, https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3002945

{Summary}

Ongoing influenza H5N1 outbreaks highlight the need for timely, scalable interventions that draw on lessons from COVID-19. In particular, successful pandemic preparedness requires early outbreak management, including effective responses targeting spillovers before there is evidence of human-to-human transmission.

____

#aH5n1 #abstract #avianInfluenza #pandemicInfluenza #pandemicPreparedness #research

Controlling minor outbreaks is necessary to prepare for major pandemics

Ongoing influenza H5N1 outbreaks highlight the need for timely, scalable interventions that draw on lessons from COVID-19. This Perspective discussed that successful pandemic preparedness requires early outbreak management, including effective responses targeting spillovers before evidence of human-to-human transmission exists.

#Drosten on the #danger of #birdflu: “I fear that the time has now been missed”

Source: T-Online, https://www.t-online.de/gesundheit/aktuelles/id_100543766/virologe-drosten-zur-h5n1-gefahr-aus-der-corona-pandemie-nichts-gelernt-.html

{Excerpt, original article in German.}

The next epidemic is spreading: the number of bird flu infections is increasing in the USA. Experts such as virologist Drosten criticize the authorities’ actions.

T-Online.de

According to experts, it is doubtful that we have learned anything from the coronavirus pandemic. In many countries, pandemic plans have been dusted off or even created in the first place. But a current example shows that in cases of doubt, too little is still being done to stop the spread of dangerous pathogens as early as possible: the H5N1 bird flu viruses in US dairy farms. Since the first detections in March, according to the US Department of Agriculture, H5N1 cases have been recorded in hundreds of farms in many states.

(…)

____

#aH5n1 #avianInfluenza #pandemicInfluenza #pandemicPreparedness

"Zeitpunkt verpasst": Virologe Drosten zur Vogelgrippe-Gefahr

Die nächste Seuche breitet sich aus: In den USA steigt die Zahl der Vogelgrippe-Infektionen. Experten wie Virologe Drosten kritisieren das Vorgehen der Behörden.

t-online

#Birdflu Cases Rise: #WHO Calls for Tight #Surveillance to Prevent #Pandemic #Risk

Source: Indozone, https://health.indozone.id/news/485366793/kasus-flu-burung-meningkat-who-serukan-pengawasan-ketat-untuk-cegah-risiko-pandemi#google_vignette

{Excerpts, article in Bahasa Indonesia.}

INDOZONE.ID – On Thursday (11/28/2024), the World Health Organization ( WHO ) called on countries around the world to increase surveillance for bird flu . This appeal came after the first case of bird flu infection was detected in a child in the United States. According to Maria Van Kerkhove, WHO’s Director of Pandemic Preparedness and Prevention, the number of H5N1 infections in humans in various countries has shown a small but significant increase in recent years. She said this at a press conference.

(…)

“We need much more robust surveillance, both in the US and in other countries, especially in animals like wild birds, poultry and other animals that are susceptible to infection, including pigs and dairy cattle. That way, we can better understand the spread of this virus in these animals,”.

Maria Van Kerkhove said, as reported by News Asia, Friday (11/29/2024)

(…)

"We have not seen any evidence of human-to-human transmission. However, every case that occurs requires a thorough investigation," he explained.

(…)

____

#aH5n1 #avianInfluenza #AVIANINFLUENZA #birdFlu #california #h5n1 #health #human #news #pandemicInfluenza #pandemicPreparedness #USA

Kasus Flu Burung Meningkat: WHO Serukan Pengawasan Ketat untuk Cegah Risiko Pandemi - Indozone Health

WHO menyerukan agar seluruh negara di dunia meningkatkan pengawasan terhadap flu burung imbas kasus anak yang terinfeksi di Amerika Serikat.

Kasus Flu Burung Meningkat: WHO Serukan Pengawasan Ketat untuk Cegah Risiko Pandemi - Indozone Health

Avian #influenza A (#H5N1) virus in dairy #cattle: #origin, #evolution, and cross-species #transmission

Source: mBio, https://journals.asm.org/doi/10.1128/mbio.02542-24

ABSTRACT
Since the emergence of highly pathogenic avian influenza virus (HPAIV) H5N1 of clade 2.3.4.4b as a novel reassortant virus from subtype H5N8, the virus has led to a massive number of outbreaks worldwide in wild and domestic birds. Compared to the parental HPAIV H5N8 clade 2.3.4.4b, the novel reassortant HPAIV H5N1 displayed an increased ability to escape species barriers and infect multiple mammalian species, including humans. The virus host range has been recently expanded to include ruminants, particularly dairy cattle in the United States, where cattle-to-cattle transmission was reported. As with the avian 2.3.4.4.b H5N1 viruses, the cattle-infecting virus was found to transmit from cattle to other contact animals including cats, raccoons, rodents, opossums, and poultry. Although replication of the virus in cows appears to be mainly confined to the mammary tissue, with high levels of viral loads detected in milk, infected cats and poultry showed severe respiratory disease, neurologic signs, and eventually died. Furthermore, several human infections with HPAIV H5N1 have also been reported in dairy farm workers and were attributed to exposures to infected dairy cattle. This is believed to represent the first mammalian-to-human transmission report of the HPAIV H5N1. Fortunately, infection in humans and cows, as opposed to other animals, appears to be mild in most cases. Nevertheless, the H5N1 bovine outbreak represents the largest outbreak of the H5N1 in a domestic mammal close to humans, increasing the risk that this already mammalian adapted H5N1 further adapts to human-to-human transmission and starts a pandemic. Herein, we discuss the epidemiology, evolution, pathogenesis, and potential impact of the recently identified HPAIV H5N1 clade 2.3.4.4b in dairy cattle in the United States. Eventually, interdisciplinary cooperation under a One Health framework is required to be able to control this ongoing HPAIV H5N1 outbreak to stop it before further expansion of its host range and geographical distribution.

_____

#aH5n1 #aH5n8 #abstract #avianInfluenza #AVIANINFLUENZA #birdFlu #cats #dairyCow #h5n1 #health #human #news #pandemicInfluenza #poultry #reassortantStrain #research #USA

  • ZABRODSKAYA YA, Gavrilova NV, Elpaeva EA, Lozhkov AA, et al
    mRNA encoding antibodies against hemagglutinin and nucleoprotein prevents influenza virus infection in vitro.
    Biochem Biophys Res Commun. 2024;738:150945.
    PubMed         Abstract available

    Biochemistry

  • YUE Z, Wu J, Teng D, Wang Z, et al
    Activation of the Influenza B M2 Proton Channel (BM2).
    Biochemistry. 2024 Nov 3. doi: 10.1021/acs.biochem.4c00607.
    PubMed         Abstract available
  • MCMINN SE, Miller DV, Yur D, Stone K, et al
    High-Throughput Algorithmic Optimization of In Vitro Transcription for SARS-CoV-2 mRNA Vaccine Production.
    Biochemistry. 2024;63:2793-2802.
    PubMed         Abstract available

    J Gen Virol

  • BOE CA, Fiskebeck EMLZ, Reiten MR, Akerstedt J, et al
    Emergence of highly pathogenic avian influenza viruses H5N1 and H5N5 in white-tailed eagles, 2021-2023.
    J Gen Virol. 2024;105:002035.
    PubMed         Abstract available

    J Immunol

  • DICK JK, Sangala JA, Krishna VD, Khaimraj A, et al
    NK Cell and Monocyte Dysfunction in Multisystem Inflammatory Syndrome in Children.
    J Immunol. 2024;213:1452-1466.
    PubMed         Abstract available

    J Infect

  • WANG H, Zhou Y, Chu L, Chen K, et al
    Guardian-driven influenza vaccination intentions for children post-COVID-19 in the 2024-2025 season: The positive spillover effects.
    J Infect. 2024;89:106333.
    PubMed        
  • HO A, McInnes N, Blunsum A, Quinn J, et al
    Near real-time severe acute respiratory illness surveillance characterising influenza and COVID-19 epidemiology in hospitalised adults, 2021-22.
    J Infect. 2024;89:106338.
    PubMed         Abstract available

    J Infect Dis

  • YEGOROV S, Brewer A, Cyr L, Ward BJ, et al
    Hemagglutination-Inhibition Antibodies and Protection against Influenza Elicited by Inactivated and Live Attenuated Vaccines in Children.
    J Infect Dis. 2024 Nov 6:jiae489. doi: 10.1093.
    PubMed         Abstract available
  • ALARCON PC, Ulanowicz CJ, Damen MSMA, Eom J, et al
    Obesity uncovers presence of inflammatory lung macrophage subsets with adipose tissue transcriptomic signature in influenza virus infection.
    J Infect Dis. 2024 Nov 4:jiae535. doi: 10.1093.
    PubMed         Abstract available

    J Neurosurg Pediatr

  • STUART MJ, Harbison AM, Ma N, Campbell RAJ, et al
    Ten-year statewide cross-sectional review of pediatric sinogenic intracranial abscess and empyema in Queensland, Australia: microbial profile before and after COVID-19.
    J Neurosurg Pediatr. 2024;34:489-494.
    PubMed         Abstract available
  • FLANDERS TM, Kumar NK, Zhao C, Joerger TA, et al
    Intracranial complications secondary to acute bacterial sinusitis requiring neurosurgical intervention before and after the onset of the COVID-19 pandemic.
    J Neurosurg Pediatr. 2024;34:479-488.
    PubMed         Abstract available

    J Virol

  • SUN X, Belser JA, Pulit-Penaloza JA, Brock N, et al
    Dissecting the role of the HA1-226 leucine residue in the fitness and airborne transmission of an A(H9N2) avian influenza virus.
    J Virol. 2024 Nov 4:e0092824. doi: 10.1128/jvi.00928.
    PubMed         Abstract available

    JAMA

  • AGARWAL SD, Cook BL, Liebman JB
    Effect of Cash Benefits on Health Care Utilization and Health: A Randomized Study.
    JAMA. 2024 Jul 22:e2413004. doi: 10.1001/jama.2024.13004.
    PubMed         Abstract available

    Pediatrics

  • WILKINS D, Wahlby Hamren U, Chang Y, Clegg LE, et al
    RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing.
    Pediatrics. 2024;154:e2024067174.
    PubMed         Abstract available

    PLoS One

  • LI X
    Where are the cruise ships? mobility and immobility of cruises under COVID-19.
    PLoS One. 2024;19:e0303216.
    PubMed         Abstract available
  • AYAZ H, Celik MH, Koytak HZ, Yanik IE, et al
    Exploring vaccine hesitancy in digital public discourse: From tribal polarization to socio-economic disparities.
    PLoS One. 2024;19:e0308122.
    PubMed         Abstract available
  • GAGNON C, Vincent T, Bherer L, Gayda M, et al
    Oxygen supplementation and cognitive function in long-COVID.
    PLoS One. 2024;19:e0312735.
    PubMed         Abstract available
  • KONDURU L, Dahia SS, Kothari-Speakman G
    Registered report: The effectiveness of a Bhagavad Gita intervention to reduce psychological distress in homeless people-A randomised controlled trial.
    PLoS One. 2024;19:e0310795.
    PubMed         Abstract available
  • PALACIOS AM, Keko M, Rochani H, Nazaruk D, et al
    A quasi-experimental study assessing the effectiveness of a community-based egg intervention in the nutritional and health status of young children from rural Honduras.
    PLoS One. 2024;19:e0312825.
    PubMed         Abstract available
  • NANTEZA MB, Nanyonjo G, Kyakuwa N, Nakanjako F, et al
    COVID-19 vaccine uptake and associated factors among individuals living in a peri-urban area in Uganda: A cross-sectional study.
    PLoS One. 2024;19:e0312377.
    PubMed         Abstract available
  • MASCLE O, Dupuis C, Brailova M, Bonnet B, et al
    Clustering based on renal and inflammatory admission parameters in critically ill patients admitted to the ICU.
    PLoS One. 2024;19:e0307938.
    PubMed         Abstract available
  • WANG M, Chi S, Wang X, Wang T, et al
    Effects of Tai Chi on anxiety and theta oscillation power in college students during the COVID-19 pandemic: A randomized controlled trial.
    PLoS One. 2024;19:e0312804.
    PubMed         Abstract available
  • AL EID NA, Arnout BA, Al-Qahtani TA, Farhan ND, et al
    Psychological flow and mental immunity as predictors of job performance for mental health care practitioners during COVID-19.
    PLoS One. 2024;19:e0311909.
    PubMed         Abstract available
  • SHABUZ ZR, Bachmann M, Cullum R, Burke A, et al
    Changes in urgent and emergency care activity associated with COVID-19 lockdowns in a sub-region in the East of England: Interrupted times series analyses.
    PLoS One. 2024;19:e0311901.
    PubMed         Abstract available
  • KUDDUS MA, Mohiuddin M, Paul AK, Rahman A, et al
    Insights from qualitative and bifurcation analysis of COVID-19 vaccination model in Bangladesh.
    PLoS One. 2024;19:e0312780.
    PubMed         Abstract available
  • ANBARCI N, Ismail MS
    AI-powered mechanisms as judges: Breaking ties in chess.
    PLoS One. 2024;19:e0305905.
    PubMed         Abstract available
  • KLEGERMAN ME, Peng T, Seferovich I, Rahbar MH, et al
    Absolute concentration estimation of COVID-19 convalescent and post-vaccination IgG antibodies.
    PLoS One. 2024;19:e0311777.
    PubMed         Abstract available

    Vaccine

  • KASAMATSU A, Yahata Y, Fukushima W, Sakamoto H, et al
    Estimating influenza vaccine effectiveness among older adults using an integrated administrative database and the implications of potential bias: A population-based cohort study in Japan.
    Vaccine. 2024;42:126488.
    PubMed         Abstract available
  • https://etidioh.wordpress.com/2024/11/10/influenza-and-other-respiratory-viruses-research-references-by-amedeo-nov-10-24/

    #avianInfluenza #COVID19 #exercise #health #influenzaA #mentalHealth #news #pandemicInfluenza #research #seasonalInfluenza #vaccines

    mRNA encoding antibodies against hemagglutinin and nucleoprotein prevents influenza virus infection in vitro - PubMed

    The emergence of new influenza virus strains presents a continuous challenge for global public health. mRNA technology offers a promising platform for rapidly developing therapeutics, particularly monoclonal antibodies, that can protect against viral infections. In this study, we engineered mRNA con …

    PubMed

    Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2024.07.14.603367v4

    Abstract
    The United States Department of Agriculture has recently released reports that show samples from 2022-2024 of highly pathogenic avian influenza (H5N1) have been detected in mammals and birds. To date, the United States Centers for Disease Control reports that there have been 27 humans infected with H5N1 in 2024. The broader potential impact on human health remains unclear. In this study, we computationally model 1,804 protein complexes consisting of various H5 isolates from 1959 to 2024 against 11 hemagglutinin domain 1 (HA1)-neutralizing antibodies. This study shows a trend of weakening binding affinity of existing antibodies against H5 isolates over time, indicating that the H5N1 virus is evolving immune escape of our medical defenses. We also found that based on the wide variety of host species and geographic locations in which H5N1 was observed to have been transmitted from birds to mammals, there is not a single central reservoir host species or location associated with H5N1’s spread. These results indicate that the virus has potential to move from epidemic to pandemic status in the near future. This study illustrates the value of high-performance computing to rapidly model protein-protein interactions and viral genomic sequence data at-scale for functional insights into medical preparedness.

    ____

    https://etidioh.wordpress.com/2024/11/09/large-scale-computational-modeling-of-h5-influenza-variants-against-ha1-neutralizing-antibodies/

    #aH5n1 #abstract #avianInfluenza #AVIANINFLUENZA #birdFlu #h5n1 #health #news #pandemicInfluenza #research

    Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2024.11.06.622244v1

    Abstract
    The current situation with H5N1 highly pathogenic avian influenza virus (HPAI) is causing a worldwide concern due to multiple outbreaks in wild birds, poultry, and mammals. Moreover, multiple zoonotic infections in humans have been reported. Importantly, HPAI H5N1 viruses with genetic markers of adaptation to mammals have been detected. Together with HPAI H5N1, avian influenza viruses H7N9 (high and low pathogenic) stand out due to their high mortality rates in humans. This raises the question of how prepared we are serologically and whether seasonal vaccines are capable of inducing protective immunity against these influenza subtypes. An observational study was conducted in which sera from people born between years 1925-1967, 1968-1977, and 1978-1997 were collected before or after 28 days or 6 months post-vaccination with an inactivated seasonal influenza vaccine. Then, haemagglutination inhibition, viral neutralization, and immunoassays were performed to assess the basal protective immunity of the population as well as the ability of seasonal influenza vaccines to induce protective responses. Our results indicate that subtype-specific serological protection against H5N1 and H7N9 in the representative Spanish population evaluated was limited or nonexistent. However, seasonal vaccination was able to increase the antibody titers to protective levels in a moderate percentage of people, probably due to cross-reactive responses. These findings demonstrate the importance of vaccination and suggest that seasonal influenza vaccines could be used as a first line of defense against an eventual pandemic caused by avian influenza viruses, to be followed immediately by the use of more specific pandemic vaccines.

    ____

    https://etidioh.wordpress.com/2024/11/09/are-we-serologically-prepared-against-an-avian-influenza-pandemic-and-could-seasonal-flu-vaccines-help-us/

    #aH5n1 #aH7n9 #abstract #avianInfluenza #AVIANINFLUENZA #birdFlu #h5n1 #health #human #news #pandemicInfluenza #research #seasonalInfluenza #serology #vaccination

    Source: MedRxIV, https://www.medrxiv.org/content/10.1101/2024.10.31.24316514v1

    Abstract
    Avian H5N1 influenza viruses are circulating widely in cattle and other mammals and pose a risk for a human pandemic. Previous studies suggest that older humans are more resistant to H5N1 infections due to childhood imprinting with other group 1 viruses (H1N1 and H2N2); however, the immunological basis for this is incompletely understood. Here we show that antibody titers to historical and recent H5N1 strains are highest in older individuals and correlate more strongly with year of birth than with age, consistent with immune imprinting. After vaccination with an A/Vietnam/1203/2004 H5N1 vaccine, both younger and older humans produced H5-reactive antibodies to the vaccine strain and to a clade 2.3.4.4b isolate currently circulating in cattle, with higher seroconversion rates in young children who had lower levels of antibodies before vaccination. These studies suggest that younger individuals might benefit more from vaccination than older individuals in the event of an H5N1 pandemic.

    ____

    https://etidioh.wordpress.com/2024/11/03/immune-history-shapes-human-antibody-responses-to-h5n1-influenza-viruses-repost/

    #aH1n1 #aH2n2 #aH5n1 #abstract #avianInfluenza #AVIANINFLUENZA #birdFlu #h5n1 #health #immunology #news #pandemicInfluenza #research #vaccination

    Immune history shapes human antibody responses to H5N1 influenza viruses

    Avian H5N1 influenza viruses are circulating widely in cattle and other mammals and pose a risk for a human pandemic. Previous studies suggest that older humans are more resistant to H5N1 infections due to childhood imprinting with other group 1 viruses (H1N1 and H2N2); however, the immunological basis for this is incompletely understood. Here we show that antibody titers to historical and recent H5N1 strains are highest in older individuals and correlate more strongly with year of birth than with age, consistent with immune imprinting. After vaccination with an A/Vietnam/1203/2004 H5N1 vaccine, both younger and older humans produced H5-reactive antibodies to the vaccine strain and to a clade 2.3.4.4b isolate currently circulating in cattle, with higher seroconversion rates in young children who had lower levels of antibodies before vaccination. These studies suggest that younger individuals might benefit more from vaccination than older individuals in the event of an H5N1 pandemic. ### Competing Interest Statement S.E.H. is a co-inventor on patents that describe the use of nucleoside-modified mRNA as a vaccine platform. S.E.H reports receiving consulting fees from Sanofi, Pfizer, Lumen, Novavax, and Merck. T.A.G. was an employee of the University of Pennsylvania when the work was completed and is now an employee of GSK. The authors declare no other competing interests. ### Funding Statement This project was funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract Nos. 75N93021C00015 (S.E.H. and S.C.) and grant numbers R01AI08686 (S.E.H.). S.E.H. holds an Investigators in the Pathogenesis of Infectious Disease Awards from the Burroughs Wellcome Fund. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Experiments using human sera were conducted with the approval of the University of Pennsylvania Institutional Review Board. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data are included in the manuscript and there are no restrictions. The code implementing the analyses is available at https://github.com/cobeylab/H5\_titers\_vs_imprinting

    medRxiv
  • WU YJ, Feng WW, Wu ZL, Zhang YY, et al
    Prim-O-glucosylcimifugin alleviates influenza virus-induced pneumonia in mice by inhibiting the TGF-beta1/PI3KCD/MSK2/RELA signalling pathway.
    Arch Virol. 2024;169:232.
    PubMed         Abstract available

    Biochem Soc Trans

  • PELLMAN J, Goldstein A, Slabicki M
    Human E3 ubiquitin ligases: accelerators and brakes for SARS-CoV-2 infection.
    Biochem Soc Trans. 2024;52:2009-2021.
    PubMed         Abstract available

    J Gen Virol

  • SAENKHAM-HUNTSINGER P, Drelich AK, Huang P, Peng BH, et al
    BALB/c mice challenged with SARS-CoV-2 B.1.351 beta variant cause pathophysiological and neurological changes within the lungs and brains.
    J Gen Virol. 2024;105:002039.
    PubMed         Abstract available

    MMWR Morb Mortal Wkly Rep

  • SUN J, Zhang Y, Zhou S, Song Y, et al
    Laboratory-Confirmed Influenza Hospitalizations During Pregnancy or the Early Postpartum Period – Suzhou City, Jiangsu Province, China, 2018-2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:958-964.
    PubMed         Abstract available
  • JONES CE, Danovaro-Holliday MC, Mwinnyaa G, Gacic-Dobo M, et al
    Routine Vaccination Coverage – Worldwide, 2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:978-984.
    PubMed         Abstract available
  • BELL J, Meng L, Barbre K, Wong E, et al
    Influenza and COVID-19 Vaccination Coverage Among Health Care Personnel – National Healthcare Safety Network, United States, 2023-24 Respiratory Virus Season.
    MMWR Morb Mortal Wkly Rep. 2024;73:966-972.
    PubMed         Abstract available

    Pediatrics

  • DYKSTRA HK, Pilkey D, Tautges J, Schnitzer PG, et al
    Characteristics of Children Ages 1-17 Who Died of COVID-19 in 2020-2022 in the United States.
    Pediatrics. 2024;154.
    PubMed         Abstract available

    PLoS Comput Biol

  • ANDRONICO A, Paireau J, Cauchemez S
    Integrating information from historical data into mechanistic models for influenza forecasting.
    PLoS Comput Biol. 2024;20:e1012523.
    PubMed         Abstract available

    PLoS One

  • PANDE S, Shamu S, Abdelhamed A, Munyao Kingoo J, et al
    COVID-19 and Female Genital Mutilation/Cutting and child marriage: An online multi-country cross sectional survey.
    PLoS One. 2024;19:e0304671.
    PubMed         Abstract available
  • IDEGUCHI S, Miyagi K, Kami W, Tasato D, et al
    Clinical features of and severity risk factors for COVID-19 in adults during the predominance of SARS-CoV-2 XBB variants in Okinawa, Japan.
    PLoS One. 2024;19:e0309808.
    PubMed         Abstract available
  • TANIGUCHI I
    The SARS-CoV-2 ORF6 protein inhibits nuclear export of mRNA and spliceosomal U snRNA.
    PLoS One. 2024;19:e0312098.
    PubMed         Abstract available
  • IMAI M, Kawakami F, Uematsu T, Matsumoto T, et al
    SARS-CoV-2 propagation to the TPH2-positive neurons in the ventral tegmental area induces cell death via GSK3beta-dependent accumulation of phosphorylated tau.
    PLoS One. 2024;19:e0312834.
    PubMed         Abstract available
  • LIU X, Luvsandagva B, Wang D, Zhu S, et al
    Impact of preexisting digestive problems on the gastrointestinal symptoms of patients with omicron variant of SARS-CoV-2 infection.
    PLoS One. 2024;19:e0312545.
    PubMed         Abstract available
  • ABERA A, Fenta EH, Woldehanna BT, Wolde FB, et al
    Impact of COVID-19 on essential healthcare services in Addis Ababa, Ethiopia: Implications for future pandemics.
    PLoS One. 2024;19:e0308861.
    PubMed         Abstract available
  • DUESTERWALD L, Nguyen M, Christensen P, Long SW, et al
    Using intrahost single nucleotide variant data to predict SARS-CoV-2 detection cycle threshold values.
    PLoS One. 2024;19:e0312686.
    PubMed         Abstract available
  • MOATASIM Y, Aboulhoda BE, Gomaa M, El Taweel A, et al
    Genetic and pathogenic potential of highly pathogenic avian influenza H5N8 viruses from live bird markets in Egypt in avian and mammalian models.
    PLoS One. 2024;19:e0312134.
    PubMed         Abstract available
  • YAMAGUCHI N, Fukumoto T, Imagita H
    Relationship between physical activity and neighborhood environment in preschool children during COVID-19.-A cross-sectional study using 24-hour activity records.
    PLoS One. 2024;19:e0304848.
    PubMed         Abstract available
  • SORNLORM K, U ES, Laohasiriwong W, Thi WM, et al
    Exploring demographic, healthcare, and socio-economic factors as predictors of COVID-19 incidence rate: A spatial regression analysis.
    PLoS One. 2024;19:e0312717.
    PubMed         Abstract available
  • ZANIB SA, Zubair T, Ramzan S, Riaz MB, et al
    A conformable fractional finite difference method for modified mathematical modeling of SAR-CoV-2 (COVID-19) disease.
    PLoS One. 2024;19:e0307707.
    PubMed         Abstract available
  • NAIDU SB, Saigal A, Shah AJ, Ogbonnaya C, et al
    Associations between ethnicity and persistent physical and mental health symptoms experienced as part of ongoing symptomatic COVID-19.
    PLoS One. 2024;19:e0312719.
    PubMed         Abstract available
  • DEZECACHE G, Chevalere J, Martinelli N, Gil S, et al
    Affiliation in times of pandemics: Determinants and consequences.
    PLoS One. 2024;19:e0306310.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  • GARAIZAR A, Diaz-Oviedo D, Zablowsky N, Rissanen S, et al
    Toward understanding lipid reorganization in RNA lipid nanoparticles in acidic environments.
    Proc Natl Acad Sci U S A. 2024;121:e2404555121.
    PubMed         Abstract available
  • ZHANG H, Wang Z, Nguyen HTT, Cornejo Pontelli M, et al
    Facilitating and restraining virus infection using cell-attachable soluble viral receptors.
    Proc Natl Acad Sci U S A. 2024;121:e2414583121.
    PubMed         Abstract available

    Vaccine

  • R MUGALI R, Ip H, Zikusooka A, Vong L, et al
    Striving for equitable vaccination coverage: Leveraging rapid coverage and community assessments during the COVID-19 pandemic to reach missed populations in Cambodia.
    Vaccine. 2024 Jun 7:S0264-410X(24)00642-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
  • MANANDHAR P, Katz J, Lama TP, Khatry SK, et al
    COVID-19 vaccine hesitancy, trust, and communication in Sarlahi District, Nepal.
    Vaccine. 2024 Jun 10:S0264-410X(24)00661-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
  • D’SOUZA S, Ghatole B, Raghuram H, Sukhija S, et al
    Understanding structural inequities in Covid-19 vaccine access and uptake among disability, transgender and gender-diverse communities in India.
    Vaccine. 2024 Aug 7:126174. doi: 10.1016/j.vaccine.2024.126174.
    PubMed         Abstract available
  • AL-DAHIR S, Hassan TAL, Moss W, Khalil A, et al
    The impact of coronavirus pandemic shutdowns on immunization completion in Hadeetha, Anbar, Iraq: A case-study of vaccine completion in a recovering healthcare system.
    Vaccine. 2024 Sep 21:126383. doi: 10.1016/j.vaccine.2024.126383.
    PubMed         Abstract available
  • MWAMBA G, Gibson EM, Toko C, Tunda C, et al
    Effective integration of COVID-19 vaccination with routine immunization: A case study from Kinshasa, DRC.
    Vaccine. 2024 Oct 4:126392. doi: 10.1016/j.vaccine.2024.126392.
    PubMed         Abstract available
  • LEIS AM, Wagner A, Flannery B, Chung JR, et al
    Evaluation of test-negative design estimates of influenza vaccine effectiveness in the context of multiple, co-circulating, vaccine preventable respiratory viruses.
    Vaccine. 2024;42:126493.
    PubMed         Abstract available
  • MACINTYRE CR, Akhtar Z, Moa A
    Corrigendum to “Influenza B/Yamagata – extinct, eradicated or hiding? [Vaccine 42/26 (2024) 126450]”.
    Vaccine. 2024 Oct 29:126486. doi: 10.1016/j.vaccine.2024.126486.
    PubMed        
  • SANCHEZ-MARTINEZ ZV, Alpuche-Lazcano SP, Stuible M, Akache B, et al
    SARS-CoV-2 spike-based virus-like particles incorporate influenza H1/N1 antigens and induce dual immunity in mice.
    Vaccine. 2024;42:126463.
    PubMed         Abstract available
  • https://etidioh.wordpress.com/2024/11/03/influenza-and-other-respiratory-viruses-research-references-by-amedeo-nov-3-24/

    #avianInfluenza #covid #COVID19 #health #influenzaA #news #pandemicInfluenza #research #seasonalInfluenza #vaccine

    Prim-O-glucosylcimifugin alleviates influenza virus-induced pneumonia in mice by inhibiting the TGF-β1/PI3KCD/MSK2/RELA signalling pathway - PubMed

    Prim-O-glucosylcimifugin (POG) is a chromone derived primarily from Saposhnikovia divaricata (Turcz) Schischk and Cimicifuga simplex. Previous research has shown that POG possesses antibacterial, anticancer, anti-inflammatory, antioxidant, anticonvulsant, antipyretic, and analgesic properties. Howev …

    PubMed

    Source: Viruses, https://www.mdpi.com/1999-4915/16/11/1728

    Abstract
    Despite the efforts of practical medicine and virology, influenza viruses remain the most important pathogens affecting human and animal health. Swine are exposed to infection with all types of influenza A, B, C, and D viruses. Influenza viruses have low pathogenicity for swine, but in the case of co-infection with other pathogens, the outcome can be much more serious, even fatal. Having a high zoonotic potential, swine play an important role in the ecology and spread of influenza to humans. In this study, we review the state of the scientific literature on the zoonotic spread of swine influenza A viruses among humans, their circulation in swine populations worldwide, reverse zoonosis from humans to swine, and their role in interspecies transmission. The analysis covers a long period to trace the ecology and evolutionary history of influenza A viruses in swine. The following databases were used to search the literature: Scopus, Web of Science, Google Scholar, and PubMed. In this review, 314 papers are considered: n = 107 from Asia, n = 93 from the U.S., n = 86 from Europe, n = 20 from Africa, and n = 8 from Australia. According to the date of publication, they are conditionally divided into three groups: contemporary, released from 2011 to the present (n = 121); 2000–2010 (n = 108); and 1919–1999 (n = 85).

    ___

    https://etidioh.wordpress.com/2024/11/01/influenza-a-viruses-in-the-swine-population-ecology-and-geographical-distribution/

    #abstract #AVIANINFLUENZA #birdFlu #disease #health #influenzaA #news #pandemicInfluenza #reassortantStrain #research #swineInfluenza

    Influenza A Viruses in the Swine Population: Ecology and Geographical Distribution

    Despite the efforts of practical medicine and virology, influenza viruses remain the most important pathogens affecting human and animal health. Swine are exposed to infection with all types of influenza A, B, C, and D viruses. Influenza viruses have low pathogenicity for swine, but in the case of co-infection with other pathogens, the outcome can be much more serious, even fatal. Having a high zoonotic potential, swine play an important role in the ecology and spread of influenza to humans. In this study, we review the state of the scientific literature on the zoonotic spread of swine influenza A viruses among humans, their circulation in swine populations worldwide, reverse zoonosis from humans to swine, and their role in interspecies transmission. The analysis covers a long period to trace the ecology and evolutionary history of influenza A viruses in swine. The following databases were used to search the literature: Scopus, Web of Science, Google Scholar, and PubMed. In this review, 314 papers are considered: n = 107 from Asia, n = 93 from the U.S., n = 86 from Europe, n = 20 from Africa, and n = 8 from Australia. According to the date of publication, they are conditionally divided into three groups: contemporary, released from 2011 to the present (n = 121); 2000–2010 (n = 108); and 1919–1999 (n = 85).

    MDPI